DHR · 10-Q · 2026Q3 · Full report

Operating Margin Drivers

DANAHER CORP /DE/ · 2026-10-21 · Importance 39 · Surprise 50 · No source text

Consolidated operating margin declined 10 basis points to 19.0% in the third quarter of 2026, but increased 180 basis points to 19.8% for the first nine months. Third-quarter margin was reduced by 130 basis points from Masimo acquisition-related inventory fair-value adjustments, 125 basis points from acquired-business dilution and 20 basis points from special long-term growth equity awards. These pressures were partly offset by 170 basis points from higher core sales, tariff refunds and operating-cost leverage, plus 85 basis points from prior-year impairment charges. Diagnostics margin fell 570 basis points in the quarter and 490 basis points year to date, while Biotechnology margin increased 680 basis points in the quarter and Life Sciences margin increased 150 basis points.

Key facts

• Higher third quarter 2026 core sales and the impact of IEEPA tariff refunds, net of changes in leverage and product mix, favorably impacted operating profit margin by 170 basis points. source
• First nine months of 2025 impairment charges related to trade names in the Life Sciences and Diagnostics segments, and impairment charges related to technology, other intangible assets and a facility in the Biotechnology segment, net of a first nine months of 2026 impairment charge related to a facility in the Biotechnology segment, favorably impacted year-to-date operating profit margin by 280 basis points. source
• Operating profit margins increased 180 basis points from 18.0% during the nine-month period ended September 26, 2025 to 19.8% for the nine-month period ended September 25, 2026. source
• Net earnings included $195 million lower year-over-year noncash charges primarily for 2025 impairment charges and unrealized investment gains/losses, net of higher intangible asset amortization, amortization of an acquisition-related inventory fair-value step-up, higher depreciation and additional stock compensation expense. source
• Impairment charges in 2025 were $101 million ($70 million after-tax or $0.10 per diluted common share) in the three-month period and $548 million ($409 million after-tax or $0.57 per diluted common share) in the nine-month period ended September 26, 2025. source
• Biotechnology operating profit as a percentage of sales was 26.4% for the three-month period ended September 25, 2026 and 19.6% for the three-month period ended September 26, 2025. source
• Diagnostics operating profit as a percentage of sales was 21.3% for the three-month period ended September 25, 2026 and 27.0% for the three-month period ended September 26, 2025. source
• The three-month period included $101 million of impairment charges recorded in the third quarter (year not fully shown in excerpt). source

Impact estimates